tetano
Editor, Senior Moderator
Cureus
. 2025 Oct 30;17(10):e95744.
doi: 10.7759/cureus.95744. eCollection 2025 Oct. Development of Multiple Autoimmune and Endocrine Disorders Following COVID-19 Vaccination: A Case Report
Abdullah M Almutairi[SUP] 1 [/SUP], Mushabab A Alshahrani[SUP] 2 [/SUP], Khalid A Albalawi[SUP] 3 [/SUP], Abdullah S Basaba[SUP] 4 [/SUP], Sabah A Roybaa[SUP] 5 [/SUP]
Affiliations
Coronavirus disease 2019 (COVID-19) vaccines have been instrumental in mitigating the pandemic, but rare post-vaccination immune-related events have been reported. Due to the brief trial period and the pressing need to begin vaccination, adverse events have been documented globally in real-time data format. There have been recent reports of new inflammatory diseases or flare-ups of immune-mediated diseases after vaccinations all over the world. Despite the low prevalence of vaccination-related side effects, it is still important to report and identify the endocrine diseases linked to the COVID-19 vaccine to facilitate prompt diagnosis and treatment. We present the case of a previously healthy 42-year-old man who developed multiple autoimmune and endocrine conditions following administration of the AstraZeneca COVID-19 vaccine. Over the course of three years following vaccination, he developed vitiligo, herpes zoster (HZ), hypothyroidism, Lambert-Eaton myasthenic syndrome (LEMS), and central adrenal insufficiency. The clinical course began with skin depigmentation and rash following the initial doses, progressing to neuromuscular and endocrine abnormalities. Comprehensive investigation and multidisciplinary treatment led to stabilization of his condition. This case highlights a potential temporal association between COVID-19 vaccination and the development of multiple autoimmune and endocrine disorders. Further investigation and long-term monitoring are necessary to better understand the mechanisms and outcomes in similar cases.
Keywords: astrazeneca; central adrenal insufficiency; covid-19 vaccine; hypothyroidism; lambert-eaton myasthenic syndrome; vitiligo.
. 2025 Oct 30;17(10):e95744.
doi: 10.7759/cureus.95744. eCollection 2025 Oct. Development of Multiple Autoimmune and Endocrine Disorders Following COVID-19 Vaccination: A Case Report
Abdullah M Almutairi[SUP] 1 [/SUP], Mushabab A Alshahrani[SUP] 2 [/SUP], Khalid A Albalawi[SUP] 3 [/SUP], Abdullah S Basaba[SUP] 4 [/SUP], Sabah A Roybaa[SUP] 5 [/SUP]
Affiliations
- PMID: 41322902
- PMCID: PMC12664288
- DOI: 10.7759/cureus.95744
Coronavirus disease 2019 (COVID-19) vaccines have been instrumental in mitigating the pandemic, but rare post-vaccination immune-related events have been reported. Due to the brief trial period and the pressing need to begin vaccination, adverse events have been documented globally in real-time data format. There have been recent reports of new inflammatory diseases or flare-ups of immune-mediated diseases after vaccinations all over the world. Despite the low prevalence of vaccination-related side effects, it is still important to report and identify the endocrine diseases linked to the COVID-19 vaccine to facilitate prompt diagnosis and treatment. We present the case of a previously healthy 42-year-old man who developed multiple autoimmune and endocrine conditions following administration of the AstraZeneca COVID-19 vaccine. Over the course of three years following vaccination, he developed vitiligo, herpes zoster (HZ), hypothyroidism, Lambert-Eaton myasthenic syndrome (LEMS), and central adrenal insufficiency. The clinical course began with skin depigmentation and rash following the initial doses, progressing to neuromuscular and endocrine abnormalities. Comprehensive investigation and multidisciplinary treatment led to stabilization of his condition. This case highlights a potential temporal association between COVID-19 vaccination and the development of multiple autoimmune and endocrine disorders. Further investigation and long-term monitoring are necessary to better understand the mechanisms and outcomes in similar cases.
Keywords: astrazeneca; central adrenal insufficiency; covid-19 vaccine; hypothyroidism; lambert-eaton myasthenic syndrome; vitiligo.